The present results argue that several tyrosine kinase inhibitors (TKIs) with known Src inhibitory activities e.g., bosutinib, dasatinib, effectively block MCL-1 antagonist-mediated MCL-1 up-regulation, and in so doing, synergistically potentiate the activity of these agents against AML cells. The gene discussed is MCL1; the disease is acute myeloid leukemia.